Anebulo Pharmaceuticals Inc ANEB
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | OTC MARKETS |
| Currency | USD |
| IPO Date | 2021-05-07 |
| Shares Out. | 40,780,000 |
| Website | anebulo.com/ ↗ |
| Phone | 17372035270 |
| Employees | 3 |
| Revenue | $0 |
| Net Income | -$2.2M |
| Total Assets | $10.7M |
| Total Liabilities | $963,821 |
| Equity | $9.7M |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Anebulo Pharmaceuticals Inc is a publicly traded company under the ticker symbol ANEB on the OTC MARKETS, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-06-01)